SCHEMBL4053111

SCHEMBL4053111

CC(=O)C(Cc1ccc(Br)nc1)C(C)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
CYP11B1 P15538 1/20 0.37
CPB2 Q96IY4 3/20 0.37
MDM2 Q00987 1/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP13 P45452 2/20 0.37
SIRT2 Q8IXJ6 1/20 0.35
LDHA P00338 2/20 0.35
FDFT1 P37268 1/20 0.35
PARP1 P09874 1/20 0.35
KCNH2 Q12809 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12568349 0.81 SIRT2 (0.38) ALDH1A1CYP11B1CPB2MMP2MMP9
SCHEMBL2073963 0.78 HSD17B10 (0.57) ALDH1A1CPB2KCNH2MEN1KMT2A
SCHEMBL2073432 0.78 HSD17B10 (0.57) ALDH1A1CPB2KCNH2MEN1KMT2A
SCHEMBL2072202 0.78 HSD17B10 (0.41) CYP11B1CPB2FDFT1
SCHEMBL2072199 0.78 HSD17B10 (0.41) CYP11B1CPB2FDFT1
SCHEMBL9317096 0.77 LDHA (0.52) MDM2LDHAESR1ESR2KMT2A
SCHEMBL1134907 0.77 GABRP (0.42) ALDH1A1CYP11B1MMP2MMP9MMP8
SCHEMBL5144527 0.77 CYP11B1 (0.40) CYP11B1CPB2MMP2MMP9MMP8
SCHEMBL4200153 0.76 ALDH1A1 (0.45) ALDH1A1CPB2MMP2MMP9MMP8
SCHEMBL17051315 0.76 CYP11B1 (0.42) CYP11B1MMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 ALDH1A1 1105/4885CYP11B1 42/4885CPB2 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.